ViaNautis Bio Monday announced partnership with Eli Lilly and Company (LLY) to use ViaNautis' proprietary drug delivery platform polyNaut in delivering genetic medicines.
ViaNautis' polyNaut, a nanovesicles platform, is designed to direct therapeutics to specific targets with precision.
As per the agreement, ViaNautis will receive an initial upfront payment from Lilly with additional milestone payments.
For comments and feedback: editorial@rttnews.com